iShares MSCI South Korea ETF vs Tilray Brands Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.36 (market cap $26.25B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: iShares MSCI South Korea ETF is far larger — about 49.5× Tilray Brands Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Tilray Brands Inc for 31 Days on average.
| EWY | TLRY | |
|---|---|---|
Market Cap | $26.25B | $530.54M |
Volume | 19,056,075 | 9,099,075 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $21.00 |
52-Week Low | $80.72 | $3.57 |
Typical Hold Time | 47 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $177.18, down 3.56% amid broad Asian market weakness driven by rising oil prices and global bond yields. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights South Korea's KOSPI volatility, with semiconductor stocks facing pressure despite strong AI demand fundamentals and corporate earnings resilience.
The outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to memory cycle trends. While AI infrastructure spending provides long-term growth potential, near-term risks include rising borrowing costs, oil price volatility, and geopolitical tensions. The ETF's heavy technology weighting creates both opportunity and vulnerability to sector-specific headwinds.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →